Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05856136 · ClinicalTrials.gov registry record · Phase 4
A Study to Investigate of the Effects of Opioid Exposure on the Ability of the Diaphragm Muscle
A Phase 4 study of Respiratory Complication and Respiratory Function Loss, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 69
- Enrollment target
- 1
- Study location
NCT05856136: Recruiting Phase 4 study of Respiratory Complication and Respiratory Function Loss, sponsored by Mayo Clinic.
NCT05856136 is a Phase 4 study of Respiratory Complication and Respiratory Function Loss that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 69 participants, below the 120-participant average among 3 other Respiratory Complication trials with a reported enrollment target (42% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05856136, a Phase 4 study of Respiratory Complication and Respiratory Function Loss, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 69 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate opioid dose effects on the ability of the diaphragm muscle to generate higher force behaviors.
Primary Outcome
Measured by the ultrasound elastography of the diaphragm muscle reported in KPa
Conditions Studied
Interventions
- DRUG Fentanyl Injection
Study Locations (1)
Minnesota
- Mayo Clinic Minnesota - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2023-06-19 |
| Est. Completion | 2026-06-01 |
| Phase | Phase 4 |
What NCT05856136 shows while recruiting
NCT05856136 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, below the 120-participant average among 3 other Respiratory Complication trials with a reported enrollment target (42% lower).
The record links to 2 conditions, with Respiratory Complication appearing as the primary indexed condition, and to 1 intervention - of which Fentanyl Injection is the first listed.
NCT05856136 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05856136 about?
NCT05856136 is a clinical study titled "A Study to Investigate of the Effects of Opioid Exposure on the Ability of the Diaphragm Muscle". The purpose of this study is to evaluate opioid dose effects on the ability of the diaphragm muscle to generate higher force behaviors.
What is the current status of trial NCT05856136?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 69 participants. The study started on 2023-06-19. Estimated completion is 2026-06-01.
What conditions does trial NCT05856136 study?
This clinical trial studies the following conditions: Respiratory Complication, Respiratory Function Loss.
What interventions are being tested in trial NCT05856136?
The interventions under investigation include: Fentanyl Injection (DRUG).
Who is sponsoring clinical trial NCT05856136?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05856136 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Complication
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI